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Copyright © 2009 JCBN Summary Currently, a standard third-line therapy for Helicobacter pylori ( H. pylori)
eradication remains to be established. Quinolones show good oral absorption, no major side
effects, and marked activity against H. pylori. Several authors have studied quinolone-based
third-line therapy and reported encouraging results, with the reported H. pylori cure rates
ranging from 60% to 84%. Resistance to quinolones is easily acquired, and the resistance rate
is relatively high in countries with a high consumption rate of these drugs. We recently
reported a significant difference in the eradication rate obtained between patients infected
with gatifloxacin-susceptible and gatifloxacin-resistant H. pylori, suggesting that the selection
of quinolones for third-line therapy should be based on the results of drug susceptibility
testing. As other alternatives of third-line rescue therapies, rifabutin-based triple therapy,
high-dose proton pump inhibitor/amoxicillin therapy and furazolidone-based therapy have
been suggested.
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Introduction
The first-line regimen for the treatment of Helicobacter
pylori (H. pylori) infection in Japan is triple therapy with a
proton pump inhibitor (PPI), amoxicillin and clarithromycin
[1, 2]. Failure of eradication of H. pylori infection with this
first-line therapy has been reported in approximately 20% of
infected patients [3, 4]. With the increase in the frequency of
clarithromycin-resistant  H. pylori, there is rising concern
about the potential decline in the eradication rate of this
infection [5]. Although 7-days’ therapy with PPI-amoxicillin-
metronidazole has been found to be effective as a second-
line regimen in patients showing failure of the first-line
regimen, approximately 10% of patients fail to respond to
even the second-line treatment [6, 7]. We recently developed
a useful predictor of the response to metronidazole-containing
second-line regimens based on the minimal inhibitory con-
centrations (MICs) of both amoxicillin and metronidazole,
and the results of the urea breath test [8]. Since a high
eradication resistance index signals a poor response to
second-line eradication therapy, patients with a high eradica-
tion resistance index may benefit from a change to other
treatment regimens selected based on the results of drug
susceptibility testing.
Currently, a standard third-line therapy still remains to be
established, and European guidelines recommend culture
before the selection of a third-line treatment based on the
microbial sensitivity to the antibiotics [9]. H. pylori isolates
after two eradication failures are often resistant to both
metronidazole and clarithromycin. Therefore, these two
drugs are not recommended for inclusion in third-line regi-
mens. The alternative candidates for third-line therapy are
quinolones, tetracycline, rifabutin, furazolidone; high-dose
PPI/amoxicillin therapy is also promising [10, 11]. Quino-
lones show good oral absorption, no major side effects and
marked activity against H. pylori [12]. A recent in vitro study
showed synergistic effects of a quinolone and PPI againstT. Nishizawa et al.
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H. pylori strains [13]. Some studies have evaluated the
efficacy of quinolones for use in a third-line regimen. Herein,
we discuss the usefulness of quinolone-based therapy as a
third-line regimen.
Quinolone Resistance and gyrA Mutation
Primary resistance of H. pylori to quinolones has been
reported to range between 2%–22% in different countries or
regions [14–21]. The prevalence of quinolone resistance is
higher in Japan, Korea and Italy (15–22%), and the preva-
lence is very low in China and Egypt (about 2%, Fig. 1).
We reported a high resistance rate (47.9%) to gatifloxacin
(8-methoxy quinolone) after eradication failure in Japan
[22]. Resistance to quinolones is easily acquired, and the
resistance rate is relatively high in countries with a high
consumption rate of these drugs [23].
Quinolones exert their antimicrobial activity by inhibiting
the enzyme DNA gyrase. This enzyme, in addition to relaxing
supercoiled DNA, introduces negative supercoils into the
DNA causing the bacterial chromosome to be maintained in
a negatively supercoiled state. In addition, the enzyme is
involved in DNA replication, recombination and transcrip-
tion. The bacterial enzyme gyrase is a tetramer consisting of
two A and two B subunits encoded by the gyrA and gyrB
genes, respectively. Quinolones exert their antimicrobial
activity at the level of the A subunit of the DNA gyrase. This
subunit, responsible for DNA cleavage and rejoining, is also
the site of action of quinolones. Several studies have shown
that the “quinolone resistance-determining region” (QRDR)
of the gyrA gene plays a critical role in the resistance of
H. pylori to quinolones [24]. H. pylori does not possess a
gene encoding topoisomerase IV, an important quinolone
target in other bacteria. We recently demonstrated a signifi-
cant association between the MICs of gatifloxacin equal to
or greater than 1 μg/mL against H. pylori and mutations of
the QPDR of the gyrA [ 22]. Furthermore, we recently
designed a rapid test based on an allele-specific polymerase
chain reaction (PCR) to detect gyrA mutations [25]. Because
the traditional culture test for bacterial susceptibility to
antibiotics is expensive and requires 10–14 days, this test is
not feasible in routine clinical practice. However, the
genotyping by allele-specific PCR takes less than 3–4 h and
the allele-specific-PCR method is useful for easy identifica-
tion of quinolone-resistant strains of H. pylori.
A few years ago, we showed the in vitro development of
gatifloxacin resistance of H. pylori strains in gatifloxacin-
containing agar culture. In these studies, four gatifloxacin and
clarithromycin-susceptible strains were serially plated onto
gatifloxacin-containing agar or clarithromycin-containing
agar, respectively, of increasing agar density. None of the
strains plated on the clarithromycin-containing agar developed
resistance to clarithromycin, until the 10th generation of
repeated culture. In contrast, all four strains plated on the
gatifloxacin-containing agar developed gatifloxacin resis-
tance, and three of these four strains had mutations of gyrA
Fig. 1. Primary resistance of H. pylori to quinolone in different countries.Quinolone-based Therapy for H. pylori Eradication
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[22]. These data suggest that resistance to quinolones is
easily acquired and widespread prescription of quinolones
may lead to the spread of resistance of H. pylori to
quinolones.
Quinolone-Based Triple Therapy
Zullo et al. [26] evaluated the efficacy of a combination
of levofloxacin-amoxicillin in 36 patients with a history of
failure of two or more therapeutic attempts. A 10-day
regimen of rabeprazole (20 mg b.i.d.), levofloxacin (250 mg
b.i.d.), and amoxicillin (1 g b.i.d.) was administered. H.
pylori was successfully eradicated in 30 patients, repre-
senting an eradication rate of 83.3% (95% confidence
interval, 71.2–95.5) and 88.2% (95% confidence interval,
77.4–99) by intention-to-treat (ITT) and per protocol (PP)
analysis, respectively. This study demonstrated that
levofloxacin-amoxicillin triple therapy administered for 10
days is a successful third-line therapeutic approach for H.
pylori eradication (Table 1).
Gisbert  et al. [ 27], in a prospective multicenter study,
managed 100 patients with a history of two consecutive
H. pylori eradication failures with a third-line levofloxacin-
based regimen. Patients with failure of a first trial of
omeprazole-clarithromycin-amoxicillin and a second trial
of omeprazole-bismuth-tetracycline-metronidazole (or raniti-
dine bismuth citrate with these antibiotics) were enrolled. A
10-day regimen consisting of omeprazole (20 mg b.i.d.),
levofloxacin (500 mg b.i.d.), and amoxicillin (1 g b.i.d.) was
administered. The eradication rates determined by PP and
ITT analyses were 66% (95% confidence interval, 56–75%)
and 60% (95% confidence interval, 50–70%), respectively,
suggesting that levofloxacin-based rescue therapy may
represent an encouraging empirical third-line strategy after
multiple previous H. pylori eradication failures.
Furthermore, Gisbert et al. [10] compared rifabutin and
levofloxacin rescue regimens in patients with two consecu-
tive H. pylori eradication failures. Patients who failed two
eradication attempts received 10 days’ treatment with either
rifabutin (150 mg b.i.d.) or levofloxacin (500 mg b.i.d.),
plus amoxicillin (1 g b.i.d.) and omeprazole (20 mg b.i.d.).
Twenty patients received rifabutin, and 20 received levo-
floxacin. The cure rate obtained by per-protocol analysis
was 45% (95% confidence interval, 26–66%) in the rifabutin
group and 81% (57–93%) in the levofloxacin group (p<0.05).
The eradication rates obtained by ITT analysis were 45%
(26–66%) and 85% (64–95%), respectively (p<0.01). This
study demonstrated that a triple levofloxacin-based rescue
regimen administered for 10 days is more effective than a
rifabutin-based triple regimen after two previous H. pylori
eradication failures.
Hsu et al. [28] designed the prospective study to assess
the efficacy of levofloxacin, amoxicillin, bismuth and
rabeprazole quadruple therapy as a third-line treatment for
H. pylori infection. The patients were 37 consecutive H.
pylori-infected patients with a history of failure of standard
first-line and second-line treatments and received a 10-day
quadruple therapy comprising rabeprazole (20 mg b.i.d.),
bismuth subcitrate (300 mg q.d.s.), amoxicillin (500 mg
q.d.s.) and levofloxacin (500 mg o.d.). H. pylori was
successfully eradicated in 84% of the patients, as determined
by both ITT analysis and PP analysis. This study suggested
that a 10-day regimen of levofloxacin and amoxicillin-based
quadruple therapy is well tolerated and yields a high eradica-
tion rate as a third-line empirical treatment regimen for H.
pylori infection [28].
Table 1. Quinolone-based regimens for third-line therapy
Author, 
year
No. of 
patients
Third-line therapy
Duration of 
therapy days
Adverse effect 
(%)
Eradication rate (%)
ITT PP
Zullo et al., 2003 36 Rabeprazole 20 mg b.i.d. 10 20.1 83.3 (30/36) 88.2 (30/34)
Levofloxacin 250 mg b.i.d.
Amoxicillin 1 g b.i.d.
Gisbert et al., 2006 100 Omeprazole 20 mg b.i.d. 10 25 60 (60/100) 66 (60/91)
Levofloxacin 500 mg b.i.d.
Amoxicillin 1 g b.i.d.
Hsu et al., 2008 37 Rabeprazole 20 mg b.i.d. 10 19 84 (31/37) 84 (31/37)
Levofloxacin 500 mg o.d.
Bismuth subcitrate 300 mg q.d.s.
Amoxicillin 500 mg q.d.s.
Nishizawa et al., 2008 11 Rabeprazole 10 mg q.d.s. 7 27.2 63.6 (7/11) 63.6 (7/11)
Gatifloxacin 400 mg o.d.
Amoxicillin 500 mg q.d.s.T. Nishizawa et al.
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Recently novel quinolones were developed, and superior
in vitro activity of gatifloxacin over that of levofloxacin
against H. pylori was reported. Furthermore, garenoxacin
(des-fluoro(6) quinolone) and sitafloxacin show activities
four-fold or greater than those of gatifloxacin [29–31].
Sharara et al. evaluated the efficacy of a 7-day regimen of
gatifloxacin (400 mg o.d.), amoxicillin (1 g b.i.d.) and
rabeprazole (20 mg b.i.d.) in 45 patients as a second-line
treatment. H. pylori was successfully eradicated in 84.4% of
the patients, as determined by both ITT analysis and PP
analysis (95% confidence interval, 74–95%) [12]. Although
the meta-analysis of Gisbert et al. showed that 10-day
regimens were more effective than 7-day regimens in the
case levofloxacin-based triple therapy, (81% vs 73%;
p<0.01) [32], gatifloxacin-based triple therapy was suffi-
ciently effective even when administered for only 7 days.
We recently investigated the efficacy of gatifloxacin-
based triple therapy as a third-line treatment for H. pylori
eradication, administered after assessment of the suscepti-
bility of the organisms to gatifloxacin and the presence of
gyrA mutations. A 7-day regimen of gatifloxacin (400 mg
o.d.), amoxicillin (500 mg q.d.s.) and rabeprazole (10 mg
q.d.s.) was administered in 11 patients. Successful eradica-
tion of H. pylori was achieved in 63.6% of the patients, as
assessed by both ITT analysis and PP analysis. The eradica-
tion rate was 100% in the patients infected with gatifloxacin-
susceptible bacteria and/or bacteria without gyrA mutations,
but only 33.3% in those infected with gatifloxacin-resistant
bacteria or bacteria with gyrA mutations. This difference
in the eradication rate between patients infected with
gatifloxacin-susceptible and gatifloxacin-resistant bacteria
was statistically significant (p<0.05). Our data suggest that
the selection of gatifloxacin for third-line therapy should be
based on the results of drug susceptibility testing or gyrA
analysis [33].
Adverse Effects
Gisbert et al. [27] reported that adverse effects occurred in
25% of the patients (23/91) administered the 10-day regimen
of levofloxacin, rabeprazole and amoxicillin, consisting
mainly of metallic taste (8%), nausea (8%), myalgia/
arthralgia (5%), and diarrhea (4%). No severe side effects
were reported.
Sharara et al. [12] reported that adverse effects occurred
in 8.9% of the patients (4/45) treated with a 7-day regimen of
gatifloxacin, rabeprazole and amoxicillin mainly consisting
of nausea, headache and mild diarrhea, none of which
necessitated discontinuation of therapy. Compliance with
the prescribed treatment was excellent. However, they
mention that clinicians should be aware of possible
alterations in the blood glucose levels, which finally leads to
the withdrawal of gatifloxacin [34], QTc interval prolonga-
tion, seizures and phototoxicity with the use of fluoro-
quinolones, especially in patients with other risk factors
for these conditions.
Conclusion
Quinolone-based rescue therapy serves as an encouraging
third-line strategy after multiple previous H. pylori eradica-
tion failures. Novel quinolones, including sitafloxacin or
garenoxacin, are more potent against H. pylori than levo-
floxacin and gatifloxacin, and switching to these quinolones
may improve third-line eradication efficacy [35]. European
guidelines recommend culture before the selection of a
third-line treatment based on microbial sensitivity to the
antibiotics. The selection of quinolones for third-line therapy
should be based on the results of drug susceptibility testing
or gyrA analysis. As other alternatives for third-line rescue
therapy, rifabutin-based triple therapy [36, 37], high-dose
PPI/amoxicillin therapy and furazolidone-based therapy, if
available, have been suggested.
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